EJHaem最新文献

{"title":"Noninvasive prenatal testing in CLL during pregnancy: A cautionary tale","authors":"Jorn L. J. C. Assmann, Diane Van Opstal, Karin E. M. Diderich, Nicole Larmonie, Yorick Sandberg","doi":"10.1002/jha2.1067","DOIUrl":"10.1002/jha2.1067","url":null,"abstract":"<p>To the Editor:</p><p>Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, with a median age at diagnosis of 72 years. An estimated 2% of the patients are females of childbearing age. CLL cases during pregnancy are rare and are associated with many complications. Although the implications and management of CLL in pregnancy have been discussed previously, issues related to noninvasive prenatal testing (NIPT) are often overlooked [<span>1</span>]. Various chromosomal changes are associated with CLL, with the deletion in the long arm of chromosome 13 at position q14 (deletion 13q14) being the most common alteration [<span>2</span>].</p><p>Since its implementation in clinical practice in 2011, NIPT was available to all pregnant women in the Netherlands in 2017. It has become a reliable and sensitive method of prenatal screening to evaluate the risk of fetal chromosomal imbalances. NIPT testing is primarily used to screen for Down (trisomy 21), Edwards (trisomy 18), or Patau (trisomy 13) syndromes. However, other deletions, such as del13q, can also be detected. NIPT can be performed as early as 10 weeks of gestations, and NIPT is based on the analysis of cell-free DNA (cfDNA) of which a small part is derived from the placenta, and the main part has a maternal origin [<span>3</span>]. However, with the NIPT test that is used in the Netherlands [<span>4, 5</span>], it is impossible to discriminate between fetal cfDNA and tumor-derived cfDNA, including CLL [<span>6</span>]. The finding of a chromosome aberration warrants further investigation using invasive prenatal procedures, such as chorionic villus sampling or amniocentesis. Maternal neoplasms causing aberrant NIPT results are a complex matter in prenatal diagnosis [<span>7</span>]. Cases describing discordant NIPT testing caused by a hematological malignancy remain very scarce [<span>8</span>], and this is the first report of a patient with diagnosed CLL having a discordant NIPT result post CLL diagnosis due to a molecular aberration of CLL cells.</p><p>A 33-year-old woman with a 1-year history of untreated CLL, had NIPT performed at 13 1/7 gestational weeks as a first-tier screening test for fetal aneuploidies. Ultrasound examinations at 6 and 12 gestational weeks showed a single viable intrauterine pregnancy, biometry appropriate for gestational age, and absence of gross fetal anomalies. The NIPT results indicated a high risk for chromosome 13q14 deletion (Figure 1). Genetic counseling of the woman and her partner was done. Our primary goal was to rule out the fetal origin of the abnormal result. Therefore, single nucleotide polymorphism array (SNP-array) on amniotic fluid cells and peripheral blood of the mother was performed to verify the abnormal NIPT result. While a mosaic loss of 10 Mb was identified in the maternal blood within the 13q14.11q14.3 region (arr[hg19] 13q14.11q14.3(40,484,657-50,909,942)x1∼2), the amniotic fluid was normal. Fluorescent in situ hy","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and treatment of T/myeloid mixed phenotype acute leukaemia (T/M-MPAL)","authors":"Ke Xu, Enas Abusalim, Evan Vitsaras, Karen Orfinada, Robert Baker, Elisabeth Nacheva, Andrew Wilson, Jenny O'Nions, Rajeev Gupta","doi":"10.1002/jha2.1075","DOIUrl":"10.1002/jha2.1075","url":null,"abstract":"<p>Dear Editor,</p><p>T/myeloid mixed phenotype acute leukaemia (T/M-MPAL) is a rare leukaemia subtype, probably accounting for <1% of all leukaemia cases [<span>1</span>]. It is characterised by immunophenotypic features of both myeloid and T-lymphoid lineages. T/myeloid MPAL is distinct from T-cell acute lymphocytic leukaemia (T-ALL) and acute myeloid leukaemia (AML) but shares significant molecular and genomic similarity to early T-cell precursor-like ALL (ETP-ALL). T/myeloid MPAL has a poorer prognosis than AML, T-ALL and ETP-ALL. Therefore, it is essential to make the correct classification. The study aimed to evaluate the T/myeloid MPAL diagnosis and review patients' treatment regimens and outcomes.</p><p>A retrospective analysis was performed of all T/M-MPAL patients treated at University College London Hospital between February/2015 and April/2022 [<span>2</span>]. The data cutoff date was 29/September/2024. The diagnosis of T/M-MPAL was made in accordance with the WHO diagnostic criteria [<span>1</span>]. Response assessments were made per European LeukemiaNet (ELN) criteria [<span>3</span>]. We reviewed bone marrow immunophenotyping (Beckman Coulter Duraclone), myeloid next-generation sequencing (NGS) (Archer VariantPlex, and TruSight Illumina) (Tables S1 and S2), fluorescence in situ hybridization (FISH) analysis, and molecular karyotyping (8 × 60K oligonucleotide arrays, Agilent) results.  For flow cytometry, bone marrow samples were prepared using T-Q Prep (Beckman Coulter), stained with a Duraclone kit (Beckman Coulter) (Table S3), and analysed on Navios flow cytometer (Beckman Coulter). Results were analysed using Kaluzo software (Beckman Coulter). Our standard diagnostic T/myeloid MPAL FISH panel consists of break apart or fusion probes targeting <i>KMT2A, CBFB::MYH11</i>, <i>RUNX1T1::RUNX1</i>, <i>PML::RARA</i>, <i>MECOM, TCRA/D</i> and probes targeting 5q, 7q, 20q and 17p (Cytocell).</p><p>Nine T/M-MPAL cases were identified among the cases of leukaemia with a median follow-up of 25 months [range 1–79 months] (Table 1). Of the nine patients, seven (78%) were male and two (22%) were female. The median age at diagnosis was 23 years old [range 13–73 years]. All patients' blast populations were positive for cCD3 (or CD3), MPO, CD34 and cCD34 and were negative for CD19 by flow cytometry. Myeloid markers CD117, CD13, and CD33 were positive at 66%, 88%, and 88%, respectively. T lymphoid markers CD2, CD5, and CD7 were positive at 55%, 44% and 100%, respectively (Table 1). Eight patients had NGS. The most common molecular abnormalities detected were <i>WT1</i> (62%), <i>NRAS/KRAS</i> (37%), and <i>BCOR</i> (25%). Additional mutations detected were <i>NOTCH</i> (12%), <i>RUNX1</i> (12%), <i>TP53</i> (12%), <i>IKZF1</i> (12%), <i>IDH2</i> (12%), and <i>U2AF1</i> (12%). Polymerase chain reaction (PCR) for <i>FLT3</i> ITD, <i>FLT3</i> TKD and <i>NPM1</i> was performed on all nine patients' samples. <i>FLT3</i> TKD was expressed at 11%, an","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of donor and recipient sex on sepsis rates and hemoglobin increment among critically ill patients receiving red cell transfusions in a retrospective study","authors":"Wenhui Li,&nbsp;Yang Liu,&nbsp;Kayla J. Lucier,&nbsp;Nancy M. Heddle,&nbsp;Jason P. Acker","doi":"10.1002/jha2.1005","DOIUrl":"10.1002/jha2.1005","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Existing research presents conflicting results on the influence of blood donor sex on hemoglobin (Hb) change and transfusion-associated infection and mortality in transfusion recipients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This retrospective study explored the association between donor and recipient sex on hospital-onset sepsis (HO-sepsis) and Hb changes in critically ill patients receiving red blood cell (RBC) transfusions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from 2010–2020 were extracted from an academic hospital's clinical database and a blood supplier's donor database. HO-sepsis was determined based on the International Classification of Diseases and Related Health Problems 10th Revision (ICD-10) diagnostic codes without requiring a microbiology test within the first 48 h of admission. Hb increments were determined by comparing the last Hb result in the 24-h period prior to RBC unit issue and the first Hb result within 4–24 h after RBC unit issued for transfusion.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>25,585 critically ill patients received one or more RBC transfusions; 3,410 were included in the HO-sepsis and 3,487 in the Hb increment analysis. There was no significant differences in the HO-sepsis rate among the four groups, but female recipients were more prone to HO-sepsis than males (OR 1.48, <i>p</i> = 0.04). Multivariate analysis found that the number of RBC unit transfused (<i>p</i> = 0.001) and recipient age (<i>p</i> = 0.03), but not recipient sex (<i>p</i> = 0.63), were significant contributors to HO-sepsis. Male blood was associated with higher Hb than female blood in female recipients (<i>p</i> = 0.007), but not in male recipients (<i>p</i> = 0.75). Variables such as donor Hb levels and recipient Hb level influenced Hb increments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Blood donor sex was not associated with HO-sepsis in critically ill patients receiving RBC transfusion. Male to female transfusions were associated with a higher Hb increment in recipients. Further exploration of the impact of sex mis-matched transfusion on recipient outcomes is warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uptake of the first to fifth doses of coronavirus disease 2019 vaccine in individuals with chronic lymphocytic leukaemia: A nationwide cohort study in Sweden","authors":"Pontus Hedberg,&nbsp;Lisa Blixt,&nbsp;Fredrik Granath,&nbsp;Peter Bergman,&nbsp;Christina Carlander,&nbsp;Soo Aleman,&nbsp;Lotta Hansson,&nbsp;the CLHIP study group","doi":"10.1002/jha2.1077","DOIUrl":"10.1002/jha2.1077","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of severe coronavirus disease 2019 (COVID-19) as well as impaired responses to COVID-19 vaccination, which may be overcome by repeated booster vaccinations. Our objective was to explore the uptake of the COVID-19 vaccine in this population since records of this are scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this nationwide cohort study, we used multiple population-based health and sociodemographic registries to study COVID-19 vaccine uptake in individuals with CLL in Sweden, from 27 December 2020 to 28 February 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 6304 individuals were included. The cumulative incidence (95% confidence interval) at the end of the study period was 95%, 94%, 88%, 78% and 56% for the first, second, third, fourth and fifth doses, respectively. The uptake was significantly higher compared with the age-standardized nationwide uptake. However, there were large disparities, especially for the fourth and fifth doses, across different age groups, birth regions, and income quartiles. These differences were especially pronounced in intersectional analyses, where individuals born abroad in the lowest income quartile had a vaccine uptake of only 49% and 24% for the fourth and fifth doses, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Even though uptake was generally high in individuals with CLL, it seems to be declining from dose three and onwards, and there are significant sociodemographic disparities in vaccine uptake.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary plasmablastic plasma cell leukemia: A diagnostic conundrum","authors":"Radu Chiriac,&nbsp;Juliette Fontaine","doi":"10.1002/jha2.1085","DOIUrl":"10.1002/jha2.1085","url":null,"abstract":"&lt;p&gt;A man in his 60s presented with a fever (39.9°C), persistent fatigue, and abnormal weight loss. Laboratory investigations revealed hypercalcemia (3.7 mmol/L), elevated LDH (880 U/L), elevated serum creatinine (2.8 mg/dL), along with anemia (67 g/L), thrombocytopenia (50 × 10&lt;sup&gt;9&lt;/sup&gt;/L), and 38% of circulating atypical-appearing lymphoid cells, varying in size and morphology, with inconspicuous nucleoli, cytoplasmic projections, and basophilic cytoplasm (Figure 1A). The absence of microscopic features characteristic of mature plasma cells hindered precise identification.&lt;/p&gt;&lt;p&gt;Bone marrow core biopsy showed massive infiltration by monomorphic, medium-sized cells with large, irregular nuclei and scant basophilic cytoplasm. The sample also exhibited a characteristic “starry-sky” appearance. Immunohistochemical staining (Figure 1B) revealed that the neoplastic cells were positive for CD138, MUM1, CCND1, BCL2, c-MYC, and kappa light chain, but negative for CD19, CD20, CD38, CD56, BCL6, ALK, and Human Herpesvirus-8 (HHV-8). The Ki-67 proliferation index was nearly 100%, with overexpression of p53 and c-MYC, and a confirmed &lt;i&gt;MYC&lt;/i&gt; rearrangement (Figure 1B, inset). In situ hybridization for Epstein-Barr virus (EBV)-encoded RNA was negative. Additionally, fluorescence in situ hybridization analysis of enriched plasma cells demonstrated a del(17)(p13.1) involving &lt;i&gt;TP53&lt;/i&gt; in 95% of cells (Figure 1C). HIV serology was negative. Serum protein electrophoresis showed no M spike but indicated hypogammaglobulinemia. The serum kappa/lambda free light chain ratio was 33.3. magnetic resonance imaging findings showed diffuse degenerative changes in the lumbar spine without vertebral collapse.&lt;/p&gt;&lt;p&gt;Given the phenotype (loss of pan-B-cell markers and expression of plasmacytic differentiation markers), bone lesions, absence of EBV and HHV-8 involvement, and myeloma-related secondary cytogenetic abnormalities (17p deletion and &lt;i&gt;MYC&lt;/i&gt; translocation), the diagnosis was more consistent with plasmablastic myeloma (PBM).&lt;/p&gt;&lt;p&gt;An autologous stem cell transplant was planned, but after the third cycle of Dara-VRd induction, the patient tested positive for severe acute respiratory syndrome coronavirus 2. Two weeks later, he was transferred to the ICU for acute respiratory distress syndrome and, a month later, died from respiratory complications due to multidrug-resistant &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt; ventilator-associated pneumonia.&lt;/p&gt;&lt;p&gt;The case demonstrates primary plasma cell leukemia with an uncommon plasmablastic morphology. The clinical presentation resembles that of acute leukemia and contrasts with classic plasma cell myeloma. The diverse morphologies of plasma cell neoplasms often mimic other hematopoietic and non-hematopoietic tumors, leading to their characterization as the “great imitator” [&lt;span&gt;1&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Differential diagnostic considerations for PBM include lymphoid neoplasms with plasmablastic, immunoblastic, or plasmacytoid features, ","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral squamous cell carcinoma in a patient affected by chronic graft versus host disease","authors":"Sem Decani,&nbsp;Giulia Ghidini,&nbsp;Niccolò Lombardi,&nbsp;Laura Moneghini,&nbsp;Elena Maria Varoni","doi":"10.1002/jha2.1069","DOIUrl":"10.1002/jha2.1069","url":null,"abstract":"&lt;p&gt;A 51-year-old Hispanic man with a history of chronic graft versus host disease (cGVHD) was referred, by his onco-haematologist, to our clinics because of a fast-growing lingual mass, in the absence of local trauma. The patient, a non-smoker, received, 4 years before, allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-id family donor for a stage IVB Epstein-Barr virus-related angioimmunoblastic T-cell lymphoma. After the HSCT, the patient developed cGVHD, with involvement of the liver, skin and oral mucosa. He was under current therapy with Sirolimus because of the worsening of hepatic values of stasis and necrosis related to the liver cGVHD. He was under follow-up and peritoneal dialysis for a drug-induced chronic renal failure.&lt;/p&gt;&lt;p&gt;Intraoral examination showed, at the left tongue apex, an exophytic, hard, red-whitish mass, surrounded by an erythroplasic lesion with a granular, irregular surface, extended to all the left side of the lingual dorsum (Figure 1). The lesion was painful during palpation. A keratotic white plaque was also detected on the lingual dorsum associated with severe tissue atrophy. Further keratotic white striae and erosions were observed at buccal and palatal mucosae, as signs of cGVHD.&lt;/p&gt;&lt;p&gt;Multiple incisional biopsies of the exophytic lingual mass and of the surrounding red area were performed. The histopathological analyses showed a micro-infiltrating oral squamous cell carcinoma (OSCC) in the context of epithelial dysplasia (Figure 2). After the oncological staging, the patient received surgical intervention and radiation therapy.&lt;/p&gt;&lt;p&gt;At a 2-year follow-up, the patient did not show any sign of recurrences.&lt;/p&gt;&lt;p&gt;Bone marrow transplanted patients are at high risk of developing solid malignancies, which can occur in up to 15% of cases and are responsible for 5%–10% of late deaths [&lt;span&gt;1, 2&lt;/span&gt;]. The mechanisms involved in cancer onset may be the results of the combined presence of cGVHD (that can occur in 60%–80% of HSCT survivors and increase the risk of OSCC 35 times), radiation and chemotherapy regimens, chronic inflammation and long-term immunosuppression [&lt;span&gt;3-5&lt;/span&gt;]. Oral cGVHD, in particular, is present in 80%–90% of patients affected by systemic cGVHD and it usually occurs as lichenoid lesions, as in this report. Oral cGVHD predisposes patients to OSCC even several years after HSCT, in the range from 1 to 22 years after the transplantation [&lt;span&gt;4, 6&lt;/span&gt;]. Consistently, our patient developed oral cancer after 4 years. These patients require lifelong multidisciplinary oral cancer screening, and the role of onco-haematologists is pivotal to guarantee OSCC early diagnosis.&lt;/p&gt;&lt;p&gt;Sem Decani, Elena Maria Varoni and Niccolò Lombardi followed the patient during diagnosis, collected the clinical data, and reviewed the manuscript. Giulia Ghidini collected clinical data and wrote the report. Laura Moneghini performed the histopathological diagnosis. Written informed","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the origin of the normal ranges of blood cell counts? An evolutionary perspective","authors":"Manon Zala,&nbsp;Vincent Alcazer,&nbsp;Laetitia Largeaud,&nbsp;Pierre Sujobert","doi":"10.1002/jha2.1073","DOIUrl":"10.1002/jha2.1073","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The normal values of the complete blood count are part of the foundational medical knowledge that is seldom questioned due to their well-established nature. These normal values are critical for optimal physiological function while minimizing the harmful consequences of an excessive number of blood cells. Thus, they represent an evolutionary trade-off likely shaped by natural selection if they significantly influence individual fitness and exhibit heritability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>On the basis of the analysis of normal blood count values of 94 mammalian species, we discovered that certain parameters are strongly associated with diet, habitat, and lifespan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Carnivorous mammals had higher hemoglobin levels than vegetarians, and aquatic mammals displayed red blood cell parameters probably selected to enhance for the diving capacities. Body weight influenced platelet counts and innate immune cells, with lighter animals having higher platelet counts and larger animals showing elevated monocytes and neutrophils.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>By treating the history of life as an experiment, we have discerned some evolutionary constraints likely contributing to the selection for optimal trade-offs in blood cell count.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia","authors":"Rafael Madero-Marroquin,&nbsp;Ryan W. Hunter,&nbsp;Caner Saygin,&nbsp;Hannah Johnston,&nbsp;Adam S. DuVall,&nbsp;Hamed Rahmani Youshanlouei,&nbsp;Clinton Osei,&nbsp;Syed Shah,&nbsp;Wendy Stock,&nbsp;Sandeep Gurbuxani,&nbsp;Anand A. Patel","doi":"10.1002/jha2.1076","DOIUrl":"10.1002/jha2.1076","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central nervous system posttransplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation successfully treated with combination therapy of acalabrutinib and immunochemotherapy: A case report and literature review","authors":"Peihao Zheng,&nbsp;Teng Xu,&nbsp;Xiaona Zuo,&nbsp;Xiaoyan Ke,&nbsp;Kai Hu","doi":"10.1002/jha2.1078","DOIUrl":"10.1002/jha2.1078","url":null,"abstract":"<p>Here, we report a case of Epstein-Barr virus-positive central nervous system-post-transplant lymphoproliferative disorder (CNS-PTLD) patient who failed to achieve complete metabolic remission (CMR) after successively trying a methotrexate-based regimen combined with orelabrutinib or whole-brain radiotherapy and encountered intracranial hemorrhage during orelabrutinib treatment. Ultimately, the patient achieved CMR after one cycle of acalabrutinib in combination with temozolomide, teniposide, liposomal doxorubicin, dexamethasone, and rituximab (TEDDi-R). Following another cycle of TEDDi-R treatment, he has been receiving acalabrutinib maintenance up to now and remained in CMR. The case may provide an effective treatment option for CNS-PTLD patients in clinical practice.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The long-term risk of immune-related conditions in survivors of diffuse large B-cell lymphoma: A Danish nationwide registry study","authors":"Laura Schou Pedersen,&nbsp;Nadja Nørholm Klausen,&nbsp;Jonas Faartoft Jensen,&nbsp;Emilis Danielsen Bacevičius,&nbsp;Peter Brown,&nbsp;Judit Mészáros Jørgensen,&nbsp;Thomas Stauffer Larsen,&nbsp;Christian Bjørn Poulsen,&nbsp;Michael Roost Clausen,&nbsp;Robert Schou Pedersen,&nbsp;Anne Ortved Gang,&nbsp;Rasmus Westermann,&nbsp;Salome Kristensen,&nbsp;Lene Wohlfahrt Dreyer,&nbsp;Tarec Christoffer El-Galaly,&nbsp;Lasse Hjort Jakobsen","doi":"10.1002/jha2.1070","DOIUrl":"10.1002/jha2.1070","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There is limited knowledge of the long-term effects on the immune system after treatment for diffuse large B-cell lymphoma (DLBCL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study included DLBCL patients from the Danish Lymphoma Registry who obtained complete remission (CR) after (R)-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like immunochemotherapy. Each R⁺ CHOP-like treated patient was matched to five comparators from the Danish background population and furthermore compared to R⁻ CHOP-like treated patients. Incidence rate ratios (IRRs) and risk differences (RDs) were calculated for a wide range of infections, autoimmune conditions, and immune deficiencies (AC-IDs) combined and by subtypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>R⁺ CHOP-like treated patients had a higher risk of infections overall (IRR 1.5, 95% confidence interval [CI] 1.4–1.7: 10-year RD 5.0%, 95% CI 2.2%–7.8%) and for a majority of the subtypes than matched comparators. Likewise, they had a higher risk of AC-IDs overall (IRR 1.4, 95% CI 1.1–1.7; RD 0.8%, 95% CI 0.7%–2.2%) than matched comparators, however only of clinical relevance for three subtypes; autoimmune diseases of the endocrine system, sarcoidosis and immune deficiencies. The addition of rituximab to CHOP-like therapy did not alter the incidence rates (IR) of infections overall (IRR 1.1, 95% CI 0.9–1.3) or AC-IDs overall (IRR 0.8, 95% CI 0.5–1.3) compared to CHOP-like therapy alone, although the IR for respiratory infections was significantly elevated (IRR 1.5, 95% CI 1.1–2.1). However, an increased use of IVIG treatment was observed among R⁺ CHOP survivors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>R-CHOP-like treated patients face an increased risk of infections and AC-IDs overall compared with the background population. The risk of infections and AC-IDs did not change overall after the addition of rituximab to CHOP, however, an increased risk of respiratory infections is notable. These findings could highlight the need for expanded vigilance and prophylaxis strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}